Advanced LNP technologies for mRNA-based therapeutics

Pantherna’s innovative platform focuses on developing advanced lipid nanoparticle (LNP) technologies for organ-specific and cell-selective delivery and expression of mRNA-based therapeutics. Through the tailored adjustment of our lipid nanoparticles, we already enable precise pharmacological targeting of diverse tissues. Our advanced LNP technologies for mRNA-based therapeutics, based on an optimized combination of PTX lipids, guarantee efficient mRNA release in target cells – for versatile and forward-thinking therapies that set new standards locally and systemically.

Our mission

Delivery technology-driven

mRNA-based drug development

Technology

Pantherna´s mRNA therapies are based on its two fundamental technology pillars, PTXmRNA™ and PTXΔLNP™, enabling robust expression of the desired protein in the correct clinical setting in order to exploit its therapeutic potential.

Read more

Translation

Our current focus is the development of a systemic mRNA therapy for pulmonary edema by restoring endothelial cell function in the lung via expression of therapeutic proteins for vascular barrier stabilization in a highly spatial manner.

Read more

Partnering

Pantherna Therapeutics is open to all types of collaborations with pharmaceutical and biotech companies.We wish to partner our in-house development programs at the pre-clinical or clinical stage.

Read more

Public funding

Details

Pantherna is supported by public funding from the EU (EFRE). EFRE is provided by the State Brandenburg  through the program “ProFIT”:

 

#80258140/ 41 ProFIT:  „Vaskularspezifische Transportsysteme für Nukleinsäure in 16761 Hennigsdorf, Neuendorfstraße 20b“

 

Mit der Durchführung des AP#3, Thema: Untersuchung der in AP#1 erforschten Testformulierungen auf immunstimulierendes Potenzial anhand diverser Vergleichsmessungen von Lipid-und Polymer-Formulierungen“ (Zeitraum vom 15.4.2021-31.12.2022), wurde die  Helmholtz-Zentrum hereon GmbH, [Institut für Aktive Polymere, Hereon Teltow, Abteilung Stammzellmodifikation und Biomaterialien, Haus M, Raum 202, Kantstr. 55, D-14513 Teltow] beauftragt.

Get in touch

    Headquarters

    Innovationsforum Hennigsdorf
    Neuendorfstrasse 20b
    D-16761 Hennigsdorf


    Phone +49(0)3302-202 240-0
    Fax: +49(0)3302-202 240-1

    Entrance area Pharma Campus Berlin
    R&D

    Bayer Pharma Campus Berlin
    Müllerstrasse 178
    S. 109
    D-13353 Berlin

     

    Phone +49 (0)30 4072 370-0